Attached files
| file | filename |
|---|---|
| EX-31 - AgeX Therapeutics, Inc. | ex-31.htm |
| EX-31 - AgeX Therapeutics, Inc. | ex31.htm |
| 10-Q - AgeX Therapeutics, Inc. | form10-q.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of AgeX Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Michael D. West, Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 14, 2020
| /s/ Michael D. West | |
| Michael D. West | |
| Chief Executive Officer | |
| /s/ Russell Skibsted | |
| Russell Skibsted | |
| Chief Financial Officer |